DiscGenics
PrivateLast Round
Series C
Aug 25, 2020
Total Funding Raised
$72.06M
Company Overview
DiscGenics is a biopharmaceutical company focused on developing regenerative cell-based therapies that provide non-surgical alternatives to alleviate pain and restore function in patients with degenerative spinal diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
DiscGenics Comps
Public and private peers based on sector, stage, and business model.
DiscGenics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Aug 25, 2020 | ||||
| Debt | Apr 14, 2020 | ||||
| Series B | Sep 26, 2017 | ||||
| Series A | Oct 5, 2011 |
Key People
Founding team and executive leadership
DiscGenics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ci:z Investment LLP | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 9, 2025
Opened a cGMP facility for scalable cell manufacturing in Salt Lake City.
DiscGenics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about DiscGenics's valuation, stock price, and market status.
